2000
DOI: 10.1097/00001813-200011000-00003
|View full text |Cite
|
Sign up to set email alerts
|

Pharmaceutical development of anticancer agents derived from marine sources

Abstract: The marine ecosystem is more and more acknowledged as a source of potential anticancer agents. After the identification of a potential substance several hurdles have to be overcome before a marine candidate can enter the clinic. Amongst these are the establishment of a method which ensures sufficient supply and, which is the focus of this review, the development of a clinically useful pharmaceutical formulation. General issues with respect to the pharmaceutical development of marine anticancer agents will be d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
34
0

Year Published

2004
2004
2020
2020

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 60 publications
(35 citation statements)
references
References 63 publications
0
34
0
Order By: Relevance
“…It is interesting to note that out of 18 preclinical investigating anticancer agents derived from marine sources, six are from sponges [45][46][47], implying that marine sponges are potential resources for new anti-cancer agents. However, there are just few reports in which the authors have screened Brazilian sponge extracts for biological activities [19][20][21][22].…”
Section: Ratio Pi Cells/ Total Cellsmentioning
confidence: 99%
“…It is interesting to note that out of 18 preclinical investigating anticancer agents derived from marine sources, six are from sponges [45][46][47], implying that marine sponges are potential resources for new anti-cancer agents. However, there are just few reports in which the authors have screened Brazilian sponge extracts for biological activities [19][20][21][22].…”
Section: Ratio Pi Cells/ Total Cellsmentioning
confidence: 99%
“…Marine invertebrates provided significant bioactive compounds including the anticancer agents psammaplins (Quiñoà and Crews, 1987;Rodriguez et al, 1987), didemnin B (Rinehart et al, 1987;Nuijen et al, 2000), dolastatin-10 (Luesch et al, 2001), ecteinascidin-743 (Rinehart et al, 1990;Wright et al, 1990) and halichondrin B (Bai et al, 1991). Currently, 62.5% (10 out of 16) of the marinederived marketed drugs or in the advanced phases of clinical trials (Phase I-Phase III) are produced by marine invertebrates, mostly sponges (Mayer et al, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…Indeed, through the combined efforts of chemists and pharmacologists, a number of sponge compounds are either already at advanced stages of clinical trials or have been selected as promising candidates for extended preclinical evaluation (Nuijen et al, 2000;Gonzalez, 2003).…”
Section: Resultsmentioning
confidence: 99%